Healthcare

For the financial year ended 30 June 2026, Cogstate Limited (ASX:CGS) reported revenue of US$60.9 million, an increase of 15%. Clinical Trials contributed US$58.4 million, while Healthcare contributed US$2.5 million. The relative size of these segments demonstrates that clinical research services account for most …

Immutep Limited (ASX:IMM; NASDAQ:IMMP) has received a cash payment of €1.36 million, or about A$2.16 million, from the French Government under its Crédit d'Impôt Recherche (CIR) program. The non-dilutive funding relates to eligible research and development activities conducted during calendar year 2025.

Adheris Health Limited (ASX:AHE) has released its Q1 FY27 quarterly activities report and Appendix 4C for the quarter ended 30 September 2026. CEO and Managing Director John Ciccio said the quarter showed steady progress, with revenue, gross profit and margin all improving on both …

Following definitive agreements with Shed Holdings on 17 July and Strive Specialties on 20 July 2026, the first patient-specific ROXUS prescriptions were fulfilled in the United States on 6 October. The final SPONTAN Phase II report showed a median Tmax of 10 minutes for …

On 30 September 2026 Vitrafy announced Versiti Blood Health as its third U.S. civilian blood partner, joining Vitalant and Hoxworth Blood Center. The agreement is aimed at advancing no-wash platelet cryopreservation, with two Guardion devices to be placed at Versiti's Blood Research Institute in …

Cohort 1 of the Phase 2 study, run with Swinburne University of Technology, treated six patients who had lived with binge eating disorder for a median of 15 years and had each failed at least one earlier treatment. All six met the primary and …

Total operating cash costs for the quarter came to $10.9 million, offset by $0.5 million of interest received, leaving the net operating outflow at $10.4 million. Research and development was the largest line at $5.7 million, up from $4.6 million in Q4 FY26 and …